Nanopharmaceutical Advanced Delivery Systems. Группа авторов
Читать онлайн книгу.
with the right drug, at the right dose, by the right dosage form, to the right target and at the right time. This requires the revolutionary discovery cracking the existing drug therapy. By this application, the possibility of side effects and ADR can be drastically minimized. There are a lot of approaches through which nanotechnology can be applicable to the development of personalized medicines, initially when contributing to the process of diagnosis is amplified, made simple, and patient-friendly. The most crucial part of personalized therapy is the analysis of genetic data of the particular individual, in particular in treating cancerous cells as they process a high variation in genetic signaling [61]. High-throughput screening of DNA sequences using nanopores is one of the best techniques to find the genetic data of the individual patient for that particular disease that helps in rapid selection of drug targets [62].
With the employment of nanostructures constructed by using carbon (carbon nanotubes) and graphene with their unique property of mechanical and electronic character, an active nanobiosensor can be developed that can detect even a lesser potent concentration of biomarkers that even a very few molecules can be estimated [63]. These nanotechnologies are combined to form a readily portable diagnostic kit—“lab on a chip” serves rapid testing and minimal biological samples to process. These devices provide an elaborated advantage by speedy diagnosis for the cancer patients at crucial stages—where earlier treatment can increase the chances of patient survival [64].
On the other hand, the tropical treatment of diabetic foot ulcer can be well facilitated with the nanoformulation facilitated by incorporating them in scaffold for their better efficacy at the site. The researcher has concluded that the incorporation of nanoformulation in the topical scaffold application promises higher bioavailability and good efficiency and reduces the cost of therapy and increases the patient acceptance leading to personalization of medicament depending upon the area of application and need [65].
3.5 Future Perceptions
Worldwide patient-centric personalized medicine is seeking a huge potential in clinical sector, though basic research in developing countries is not up to par to that of Western countries. The ever-developing fields of nanotechnology, nanomedicines, nanobiotechnology, and genomic studies in the continuous multidisciplinary research open up a new trend set in developing personalized and customized drug delivery systems. Still there are various pitfalls and limitations such as toxicity, bioethical issues, safety, pharmaceutical development, and physiological challenges that are associated with the available technologies that paved the way to a new set of objectives and goals for future scientists to research the emerging technologies for better and more patient-centric therapy. On the other hand, the nanotechnology and personalized medicine are still devoid of enough regulatory guidelines and data with respect to safety of the materials utilized in the formulation developed and the medications. In the forthcoming days, the nanotechnology serves an advantage of affecting the route of administration starting from oral to injectables offering significantly higher impact in the concept of personalization and customization of medicines, drug delivery, and therapy.
3.6 Conclusion
The two major factors that affect the personalized medicine application are the choice of drug and technology tool to opt as a part of genetic testing and the validation of the choice of drug and the tool. As discussed above, the wise use of nanotechnology tools in customizing drug delivery improves the currently existing drug therapy by increasing the patient compliances and reducing the adverse drug reaction and side effects. It also emphasizes the need of pharmacogenetic and pharmacogenomic data for a better excise of the diagnostic, prevention, and treatment models present. An implication of nanotechnological tools in personalized medicines is the initial growth in the field of clinical and patient care approaches. Still, various undiscovered technologies by utilizing genetic data that are available for decades are the future upcoming scopes for better therapy of diseases. The collaborated researches combining nanotechnologies, biotechnology, and the concept of personalized medicines yields a patient-centric diagnosis and treatment technology. From the traditionally available conventional dosage forms such as tablets, capsules, and ointments, solutions are being customized by introducing nanodrug delivery incorporated into the available delivery systems in accordance with the patient’s diagnostic needs for better accurate treatment. In the future, the booming field of personalized medicines and the existing nanotechnology approach an increased application for the treatment of patient-centric drug delivery.
References
1. Nikalje, A.P., Nanotechnology and its applications in medicine. Med. Chem., 5, 2, 81–89, 2015.
2. Torchilin, V.P., Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS PharmSciTech, 9, 128–147, 2007.
3. Lombardo, D., Kiselev, M.A., Caccamo, M.T., Smart Nanoparticles for Drug Delivery Application: Development of Versatile Nanocarrier Platforms in Biotechnology and Nanomedicine. J. Nanomater., 2019, Article ID 3702518, 26 pages, 2019. https://doi.org/10.1155/2019/3702518
4. Patra, J.K., Das, G., Fraceto, L.F., Nano based drug delivery systems: recent developments and future prospects. J. Nanobiotechnol., 16, 71, 2018.
5. Din, F. u., Aman, W., Ullah, I., Qureshi, O.S., Mustapha, O., Shafique, S., Zeb, A., Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int. J. Nanomedicine, 12, 7291–7309, 2017.
6. Wang, E.C. and Wang, A.Z., Nanoparticles and their applications in cell and molecular biology. Integr. Biol., 6, 1, 9–26, 2014.
7. Boholm, M., The use and meaning of nano in American English: Towards a systematic description. Ampersand, 3, 163–173, 2016.
8. Gunasekaran, T., Haile, T., Nigusse, T., Dhanaraju, M.D., Nanotechnology: An effective tool for enhancing bioavailability and bioactivity of phytomedicine. Asian Pac. J. Trop. Biomed., 4, 1–7, 2014.
9. Wang, L., The antimicrobial activity of nanoparticles: present situation and prospects for the future. Int. J. Nanomedicine, 12, 1227–1249, 2017.
10. Lohani, A., Verma, A., Joshi, H., Yadav, N., Karki, N., Nanotechnology-based cosmeceuticals. ISRN Dermatol., 2014, 843687, 2014.
11. Bisht, G. and Rayamajhi, S., ZnO Nanoparticles: A Promising Anticancer Agent. Nanobiomedicine, 3, 9, 2016.
12. Ventola, C.L., Direct-to-Consumer Pharmaceutical Advertising: Therapeutic or Toxic? Pharm. Ther., 36, 10, 669–684, 2011.
13. Vogenberg, F.R., Isaacson Barash, C., Pursel, M., Personalized medicine: part 1: evolution and development into theranostics. Pharm. Ther., 35, 10, 560–576, 2010.
14. Radhakrishnan, A., Kuppusamy, G., Ponnusankar, S., Shanmukhan, N.K., Pharmacogenomic phase transition from personalized medicine to patient-centric customized delivery. Pharmacogenomics J., 20, 1–18, 2020.
15. Mathur, S. and Sutton, J., Personalized medicine could transform healthcare. Biomed. Rep., 7, 1, 3–5, 2017.
16. Bengsch, B., Thimme, R., Blum, H.E., IndividualisierteMedizin 2011. Gastroenterologe, 6, 2, 106–111, 2011.
17. Luo, J.-H., Ren, B., Keryanov, S., Tseng, G.C., Rao, U.N.M., Monga, S.P., Strom, S., Demetris, A.J., Nalesnik, M., Yu, Y.P., Ranganathan, S., Michalopoulos, G.K., Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology, 44, 1012–1024, 2006.
18. Spear, B.B., Heath-Chiozzi, M., Huff, J., Clinical application of pharmacogenetics. Trends Mol. Med., 7, 5, 201–204, 2001.
19. Abrahams, E. and Silver, M., The case for personalized medicine. J. Diabetes Sci. Technol., 3, 4, 680–684, 2009.
20. Roden, D.M., Wilke, R.A., Kroemer, H.K., Stein, C.M., Pharmacogenomics: the genetics of variable drug responses. Circulation, 123, 15, 1661–1670, 2011.
21.